 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌhɛksoʊˈprɛnəliːn/HEKS-oh-PREN-ə-leen |
| Other names | 4-[2-[6-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets),IV |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 5–11% (Tmax = 2 hours) |
| Metabolism | COMT (slowO-methylation) |
| Eliminationhalf-life | ~50 minutes (if taken orally) |
| Excretion | Feces (~90%)[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H32N2O6 |
| Molar mass | 420.506 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Hexoprenaline is a selectiveβ2 adrenergic receptoragonist used in the treatment ofasthma.[2] Hexoprenaline is also used in some countries (such asRussia andSwitzerland) as atocolytic agent (i.e., labor suppressant), with the most common trade name beingGynipral.[3][4] It is not approved by the United StatesFood and Drug Administration.
When used as a tocolytic, hexoprenaline is contraindicated in:
It should be used with caution in people withgestational diabetes.
When concomitantly administered:
Hexoprenaline is contraindicated for use withmonoamine oxidase inhibitors (MAOIs),tricyclic antidepressant (TCAs),ergot alkaloids, anddihydrotachysterol.[3]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
